Wells Fargo’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Wells Fargo’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175	Sell	59 -66	-53%	-$206	﹤0.01%	6606
2026 Q1	$388	Hold	125	–	–	﹤0.01%	6418
2025 Q4	$500	Sell	125 -10	-7%	-$78	﹤0.01%	6334
2025 Q3	$1.67K	Hold	135	–	–	﹤0.01%	6208
2025 Q2	$2.83K	Hold	135	–	–	﹤0.01%	6162
2025 Q1	$4K	Buy	135 +10	+8%	+$319	﹤0.01%	6059
2024 Q4	$4.06K	Hold	125	–	–	﹤0.01%	6096
2024 Q3	$5.03K	Buy	+125	New	+$6.69K	﹤0.01%	5914
2022 Q2	–	Sell	-8	Closed	-$2K	–	6841
2022 Q1	$2K	Hold	8	–	–	﹤0.01%	6652
2021 Q4	$2K	Hold	8	–	–	﹤0.01%	6868
2021 Q3	$2K	Hold	8	–	–	﹤0.01%	6553
2021 Q2	$3K	Hold	8	–	–	﹤0.01%	6445
2021 Q1	$4K	Buy	+8	New	+$3.47K	﹤0.01%	6532

Other funds holding CANF

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo's CANF Position: Q2 2026 in Review

Wells Fargo reduced its Can-Fite BioPharma American Depositary Shares (CANF) stake by 53% in Q2 2026, selling an estimated $206 and leaving 59 shares worth $175. The position accounts for ﹤0.01% of the portfolio, ranked #6606.

Wells Fargo first reported a position in CANF in Q1 2021 and has held it in 13 quarters since. The position peaked at $5.03K in Q3 2024. 8 funds tracked by Wall St. Rank hold CANF as of Q2 2026.

Wells Fargo held 59 shares of Can-Fite BioPharma American Depositary Shares worth $175 as of Q2 2026.
Wells Fargo sold 66 Can-Fite BioPharma American Depositary Shares shares in Q2 2026, an estimated $206.
Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6606 holding.
Wells Fargo first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2021 and has held it in 13 quarters since.
Wells Fargo's Can-Fite BioPharma American Depositary Shares position peaked at $5.03K in Q3 2024.
8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.